PubRank

Keith L Ligon

Author PubWeight™ 161.13‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007 17.20
2 Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007 10.60
3 p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 2006 9.09
4 Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 2009 5.63
5 Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002 5.11
6 p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008 5.00
7 Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. Cancer Res 2006 4.80
8 Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell 2008 4.71
9 Acquisition of granule neuron precursor identity is a critical determinant of progenitor cell competence to form Shh-induced medulloblastoma. Cancer Cell 2008 4.68
10 Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012 4.37
11 Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev 2012 3.44
12 FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. Cell Stem Cell 2009 3.37
13 Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet 2013 3.19
14 A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006 3.06
15 Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 2012 2.84
16 Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 2013 2.82
17 Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 2013 2.42
18 Rapid, label-free detection of brain tumors with stimulated Raman scattering microscopy. Sci Transl Med 2013 2.31
19 Myelin gene regulatory factor is a critical transcriptional regulator required for CNS myelination. Cell 2009 2.18
20 BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. PLoS One 2011 2.04
21 Human glioma growth is controlled by microRNA-10b. Cancer Res 2011 1.96
22 Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proc Natl Acad Sci U S A 2013 1.95
23 Embryonic stem cell transcription factor signatures in the diagnosis of primary and metastatic germ cell tumors. Am J Surg Pathol 2007 1.92
24 The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma. Cancer Cell 2011 1.92
25 Myelin abnormalities without oligodendrocyte loss in periventricular leukomalacia. Brain Pathol 2008 1.87
26 Molecular diversity of astrocytes with implications for neurological disorders. Proc Natl Acad Sci U S A 2004 1.76
27 Classifying human brain tumors by lipid imaging with mass spectrometry. Cancer Res 2011 1.71
28 Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Ann Neurol 2007 1.64
29 DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nat Genet 2013 1.64
30 International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 2011 1.53
31 Phase II study of protracted daily temozolomide for low-grade gliomas in adults. Clin Cancer Res 2009 1.52
32 Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry. Angew Chem Int Ed Engl 2010 1.43
33 Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids 2013 1.38
34 Histology-based expression profiling yields novel prognostic markers in human glioblastoma. J Neuropathol Exp Neurol 2005 1.34
35 Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm. Genome Res 2013 1.33
36 Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A 2013 1.33
37 Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 2012 1.33
38 Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Cancer Res 2007 1.32
39 Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. Genome Res 2013 1.31
40 Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol 2009 1.30
41 Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. Proc Natl Acad Sci U S A 2010 1.21
42 Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. Nat Med 2013 1.19
43 Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol 2008 1.18
44 Development of stereotactic mass spectrometry for brain tumor surgery. Neurosurgery 2011 1.16
45 Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. Acta Neuropathol 2014 1.15
46 BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper. J Neuropathol Exp Neurol 2012 1.14
47 Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. Clin Cancer Res 2009 1.11
48 Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn 2011 1.11
49 SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest 2014 1.10
50 Diffusion-weighted imaging of fungal cerebral infection. AJNR Am J Neuroradiol 2005 1.10
51 Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol 2006 1.10
52 Neoplastic cells are a rare component in human glioblastoma microvasculature. Oncotarget 2012 1.09
53 Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. Proc Natl Acad Sci U S A 2011 1.09
54 Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol 2014 1.06
55 Disruption of diacylglycerol kinase delta (DGKD) associated with seizures in humans and mice. Am J Hum Genet 2007 1.06
56 Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One 2012 1.06
57 Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 2010 1.03
58 DNA fragmentation simulation method (FSM) and fragment size matching improve aCGH performance of FFPE tissues. PLoS One 2012 1.02
59 Prospective, high-throughput molecular profiling of human gliomas. J Neurooncol 2012 1.02
60 Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema. J Pediatr 2003 1.01
61 PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol 2013 1.00
62 Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution. J Mol Diagn 2007 0.98
63 D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 2014 0.97
64 CRX is a diagnostic marker of retinal and pineal lineage tumors. PLoS One 2009 0.97
65 Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol 2013 0.96
66 Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol 2012 0.92
67 Array-based genomics in glioma research. Brain Pathol 2009 0.90
68 Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech 2012 0.88
69 Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. Pediatr Blood Cancer 2012 0.87
70 Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy. Stem Cells 2014 0.86
71 Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. J Neurooncol 2014 0.85
72 Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. Dev Biol 2006 0.85
73 Integrative functional genomics identifies RINT1 as a novel GBM oncogene. Neuro Oncol 2012 0.84
74 Comparative analysis of germ cell transcription factors in CNS germinoma reveals diagnostic utility of NANOG. Am J Surg Pathol 2006 0.82
75 Enhancing radiation therapy for patients with glioblastoma. Expert Rev Anticancer Ther 2013 0.79
76 Myxopapillary ependymomas in children: imaging, treatment and outcomes. J Neurooncol 2016 0.77
77 Glioma models: new GEMMs add "class" with genomic and expression correlations. Cancer Cell 2011 0.77
78 Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. Am J Surg Pathol 2017 0.75
79 A novel TP53 germline mutation in a family with a history of multiple malignancies: case report and review of the literature. Pediatr Neurosurg 2009 0.75